• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

将利斯的明贴片贴到颈后不当导致中毒症状。

Improper Application of a Rivastigmine Patch to the Back of the Neck Induced Toxic Symptoms.

机构信息

Division of Neurology, Department of Medicine, Jichi Medical University, Japan.

Department of Internal Medicine, Imai Hospital, Japan.

出版信息

Intern Med. 2023 Nov 1;62(21):3247-3250. doi: 10.2169/internalmedicine.1236-22. Epub 2023 Mar 22.

DOI:10.2169/internalmedicine.1236-22
PMID:36948626
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10686733/
Abstract

Rivastigmine is a highly effective drug for treating Alzheimer's disease. However, its addiction can be fatal, so proper use of this transdermal drug is needed. We herein report an 85-year-old woman with Alzheimer's disease who inappropriately placed rivastigmine patches on the back of her neck. She suffered from acute cholinergic syndrome, hypersalivation, anorexia, dyspnea, and vomiting. These symptoms disappeared when the improper use of rivastigmine patches was ceased. This case serves as a warning to physicians and pharmacists of the risk associated with the improper placement of rivastigmine patches.

摘要

利斯的明是一种治疗阿尔茨海默病的高效药物。然而,它有成瘾性,可能致命,因此需要正确使用这种透皮药物。我们在此报告一例 85 岁女性阿尔茨海默病患者,她将利斯的明贴片不当贴在颈后。她出现了急性胆碱能综合征,表现为流涎、厌食、呼吸困难和呕吐。停止使用利斯的明贴片后,这些症状消失。此病例提醒医生和药剂师注意利斯的明贴片不当放置的风险。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ace/10686733/a9af02cfc994/1349-7235-62-3247-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ace/10686733/a9af02cfc994/1349-7235-62-3247-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ace/10686733/a9af02cfc994/1349-7235-62-3247-g001.jpg

相似文献

1
Improper Application of a Rivastigmine Patch to the Back of the Neck Induced Toxic Symptoms.将利斯的明贴片贴到颈后不当导致中毒症状。
Intern Med. 2023 Nov 1;62(21):3247-3250. doi: 10.2169/internalmedicine.1236-22. Epub 2023 Mar 22.
2
Acute cholinergic syndrome in a patient with mild Alzheimer's type dementia who had applied a large number of rivastigmine transdermal patches on her body.一名患有轻度阿尔茨海默病型痴呆的患者,在身上大量使用了多奈哌齐透皮贴剂后出现急性胆碱能综合征。
Clin Toxicol (Phila). 2017 Nov;55(9):1008-1010. doi: 10.1080/15563650.2017.1329536. Epub 2017 Jun 8.
3
Real-world Utilisation of the Rivastigmine Transdermal Patches Accompanying the Use of Risk Minimisation Tools in Patients with Dementia.伴随使用风险最小化工具,在痴呆患者中瑞伐斯的明透皮贴片的真实世界应用。
Curr Alzheimer Res. 2021;18(4):273-282. doi: 10.2174/1567205018666210716120540.
4
Spotlight on rivastigmine transdermal patch: in dementia of the Alzheimer's type.聚焦利斯的明透皮贴剂:用于治疗阿尔茨海默病型痴呆。
Drugs Aging. 2011 Nov 1;28(11):927-30. doi: 10.2165/11207090-000000000-00000.
5
Efficacy of rivastigmine tartrate, transdermal system, in Alzheimer's disease.酒石酸卡巴拉汀透皮贴剂治疗阿尔茨海默病的疗效
Expert Opin Pharmacother. 2016;17(6):861-70. doi: 10.1517/14656566.2016.1159296.
6
Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type.利斯的明透皮贴剂:用于治疗阿尔茨海默病型痴呆的临床评价。
Drugs. 2011 Jun 18;71(9):1209-31. doi: 10.2165/11206380-000000000-00000.
7
Transdermal rivastigmine: management of cutaneous adverse events and review of the literature.经皮利伐斯的明:皮肤不良反应的管理和文献回顾。
CNS Drugs. 2011 Jul;25(7):575-83. doi: 10.2165/11592230-000000000-00000.
8
Rivastigmine Patch in Chinese Patients with Probable Alzheimer's disease: A 24-week, Randomized, Double-Blind Parallel-Group Study Comparing Rivastigmine Patch (9.5 mg/24 h) with Capsule (6 mg Twice Daily).利斯的明透皮贴剂治疗中国轻、中度阿尔茨海默病患者的 24 周随机、双盲、平行分组研究:比较利斯的明透皮贴剂(9.5 mg/24 h)与胶囊(每日 2 次、每次 6 mg)。
CNS Neurosci Ther. 2016 Jun;22(6):488-96. doi: 10.1111/cns.12521. Epub 2016 Mar 25.
9
Rivastigmine for Alzheimer's disease.卡巴拉汀用于治疗阿尔茨海默病。
Cochrane Database Syst Rev. 2009 Apr 15(2):CD001191. doi: 10.1002/14651858.CD001191.pub2.
10
Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease.重酒石酸卡巴拉汀透皮贴剂的皮肤耐受性:轻度至中度阿尔茨海默病患者 1 年临床试验结果。
Clin Drug Investig. 2010;30(1):41-9. doi: 10.2165/11531270-000000000-00000.

本文引用的文献

1
Effects of anatomical location on percutaneous penetration in man.解剖部位对人体经皮渗透的影响。
Cutan Ocul Toxicol. 2020 Sep;39(3):213-222. doi: 10.1080/15569527.2020.1787434. Epub 2020 Jul 9.
2
Efficacy of rivastigmine transdermal therapy on low food intake in patients with Alzheimer's disease: The Attitude Towards Food Consumption in Alzheimer's Disease Patients Revive with Rivastigmine Effects study.多奈哌齐透皮贴剂治疗阿尔茨海默病患者低食欲的疗效:多奈哌齐对阿尔茨海默病患者摄食态度影响的研究。
Geriatr Gerontol Int. 2019 Jul;19(7):571-576. doi: 10.1111/ggi.13644. Epub 2019 Mar 12.
3
Transspinal delivery of drugs by transdermal patch back-of-neck for Alzheimer's disease: a new route of administration.
通过颈部后侧经皮贴片经脊柱给药治疗阿尔茨海默病:一种新的给药途径。
Discov Med. 2019 Jan;27(146):37-43.
4
Rivastigmine Improves Appetite by Increasing the Plasma Acyl/Des-Acyl Ghrelin Ratio and Cortisol in Alzheimer Disease.卡巴拉汀通过提高阿尔茨海默病患者血浆酰基/去酰基胃饥饿素比值和皮质醇水平来改善食欲。
Dement Geriatr Cogn Dis Extra. 2018 Mar 13;8(1):77-84. doi: 10.1159/000487358. eCollection 2018 Jan-Apr.
5
An update on the safety of current therapies for Alzheimer's disease: focus on rivastigmine.阿尔茨海默病当前治疗方法的安全性更新:聚焦于卡巴拉汀
Ther Adv Drug Saf. 2018 Mar;9(3):171-178. doi: 10.1177/2042098617750555. Epub 2018 Jan 8.
6
Acute cholinergic syndrome in a patient with mild Alzheimer's type dementia who had applied a large number of rivastigmine transdermal patches on her body.一名患有轻度阿尔茨海默病型痴呆的患者,在身上大量使用了多奈哌齐透皮贴剂后出现急性胆碱能综合征。
Clin Toxicol (Phila). 2017 Nov;55(9):1008-1010. doi: 10.1080/15563650.2017.1329536. Epub 2017 Jun 8.
7
Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada.根据美国和加拿大的药物警戒数据库,胆碱酯酶抑制剂在痴呆症中的不良反应
PLoS One. 2015 Dec 7;10(12):e0144337. doi: 10.1371/journal.pone.0144337. eCollection 2015.
8
Transdermal Drug Delivery: Innovative Pharmaceutical Developments Based on Disruption of the Barrier Properties of the stratum corneum.经皮给药:基于破坏角质层屏障特性的创新药物研发。
Pharmaceutics. 2015 Oct 22;7(4):438-70. doi: 10.3390/pharmaceutics7040438.
9
Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review.新型透皮利斯的明贴片治疗阿尔茨海默病的药代动力学:综述。
Int J Clin Pract. 2009 May;63(5):799-805. doi: 10.1111/j.1742-1241.2009.02052.x.
10
Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline.胆碱酯酶抑制剂和美金刚治疗痴呆的有效性:临床实践指南的证据综述
Ann Intern Med. 2008 Mar 4;148(5):379-97. doi: 10.7326/0003-4819-148-5-200803040-00009.